News | Cardiogenic Shock | March 22, 2023

Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office

New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039

New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039

March 22, 2023 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,583,540, providing expanded patent coverage for istaroxime administration. 

Istaroxime is an investigational drug candidate being studied in early cardiogenic shock and acute heart failure. It has a novel dual mechanism of action that increases both systolic contraction and diastolic relaxation, uniquely addressing heart failure associated SERCA2a dysfunction. SERCA2a activation facilitates sequestration of calcium during diastole, favoring relaxation and making more calcium available for the next contraction, further improving cardiac ventricular function. Phase 2a and Phase 2b studies in acute heart failure have demonstrated significant improvements in cardiac function as well as increasing blood pressure and preserving or increasing renal function. 

The new U.S. patent, titled: “Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF)”, is a continuing patent following the expedited U.S. Track One filing by Windtree, which resulted in U.S. Patent No. 11,197,869 that issued December 14, 2021. The claims of the newly issued patent cover longer durations of istaroxime infusion for improved outcomes in treatment of acute heart failure. In particular, the claims are directed to an improvement in diastolic heart function following administration of istaroxime by intravenous infusion for 6 hours or more, which Windtree attributes to the SERCA2a mechanism of action of istaroxime and its metabolites. 

“Windtree continues to strengthen the patent estate for istaroxime with this new issuance from the USPTO,” said Craig Fraser, CEO and President of Windtree Therapeutics. “We believe istaroxime is differentiated from other drugs that are used to treat acute decompensated heart failure and this patent provides additional rationale for how it can provide unique benefits to potential patients. We plan to continue this work to further expand istaroxime’s patent estate in the clinical development work ahead.” 

For more information: https://windtreetx.com/ 

Related Content:  

Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America  

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock  

Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime 


Related Content

News | Cardiovascular Clinical Studies

June 7, 2023 — The U.S. Food and Drug Administration (FDA) has announced the availability of a draft guidance with ...

Home June 07, 2023
Home
News | Cardiovascular Clinical Studies

April 20, 2023 — Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed ...

Home April 20, 2023
Home
News | Cardiovascular Clinical Studies

April 5, 2023 — Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced the release of a new study ...

Home April 05, 2023
Home
News | Cardiovascular Clinical Studies

March 29, 2023 — Irregular sleep patterns may play a role in the pathophysiologic development of cardiovascular disease ...

Home March 29, 2023
Home
News | Cardiovascular Clinical Studies

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home March 27, 2023
Home
News | Cardiovascular Clinical Studies

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of ...

Home March 24, 2023
Home
News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
Home
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
Home
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
Subscribe Now